A severe case of thrombocytopenia, anasarca, fever, renal insufficiency or reticulin fibrosis, and organomegaly syndrome with myocardial and skeletal muscle calcification despite hypocalcemia: a case report

Shogo Minomo1*, Yu Fujiwara2,3, Shota Sakashita4, Akito Takamura5 and Kaoru Nagata1

Abstract
Background: TAFRO (thrombocytopenia, anasarca, fever, renal insufficiency or reticulin fibrosis, and organomegaly) syndrome is a recently recognized disease with a variety of presentations of variable severity. In acute settings, this disease also involves organ dysfunction because of the associated systemic inflammation. However, cases of TAFRO syndrome with myocardial and/or skeletal muscle calcification have never been reported.

Case presentation: A 24-year-old healthy young Asian man was admitted with intermittent epigastric pain and fever for 2 weeks. Computed tomography revealed pleural effusion, ascites and systemic lymphadenopathy. Laboratory tests showed thrombocytopenia, elevated C-reactive protein, hypoalbuminemia, anemia and renal dysfunction. Based on these findings and bone marrow biopsy, we diagnosed his disease as TAFRO syndrome and commenced hemodialysis for the renal dysfunction. However, he developed refractory hypocalcemia with unstable vital signs, for which we administered calcium gluconate hydrate. Thereafter, myocardial and skeletal muscle calcification was revealed radiologically, with the myocardial calcification causing sick sinus syndrome. He was treated with tocilizumab and finally discharged in an ambulatory condition after prolonged hospitalization, with residual calcific lesions.

Conclusion: This is the first report of a patient with TAFRO syndrome and the complication of organ calcification. The etiology of calcification in this case is not clear. Systemic inflammation with possible hypercytokinemia might have been involved in the unexpected complication of systemic calcification. It is important to carefully handle the general management of TAFRO syndrome because of the possibility of various complications.

Keywords: TAFRO syndrome, Myocardial calcification, Skeletal muscle calcification, Hypocalcemia, Tocilizumab

Background
TAFRO (thrombocytopenia, anasarca, fever, renal insufficiency or reticulin fibrosis, organomegaly) syndrome is a systemic inflammatory disease first reported by Takai et al. in 2010 [1], and is categorized as a subtype of idiopathic multicentric Castleman’s disease (iMCD). TAFRO syndrome follows a particularly aggressive clinical course compared to unicentric Castleman’s disease or other subtypes of iMCD. Therefore, clinicians often experience difficulty in treating this condition. Since its earliest description, reports of cases of TAFRO syndrome have been described worldwide, and guidelines for its treatment have been proposed [2–5]. Since organ dysfunction...
is commonly seen with TAFRO syndrome, temporary hemodialysis is often necessary during the course of treatment of this condition [2], although no case reports have described calcific deposits associated with hemodialysis. Additionally, although several cases with severe cardiac dysfunction due to chemotherapy, hypercytokinemia and massive ascites have been reported [6–8], there have been no cases of gross calcification recognized radiologically, either in the myocardium or in skeletal muscles.

We report a case of TAFRO syndrome with myocardial and skeletal muscle calcification, who was finally discharged from the hospital in an ambulatory condition following tocilizumab therapy. Our patient also presented with severe hypocalcemia during his clinical course, the treatment of which might have eventually triggered systemic calcification. Although it is difficult to completely understand the etiological mechanism in this case, our experience will contribute to understanding the pathophysiology and general management of TAFRO syndrome.

Case presentation

A previously healthy 24-year-old Asian man without significant family medical history presented with intermittent severe epigastric pain and fever for two weeks. Since a computed tomography (CT) scan at another hospital had only revealed systemic lymphadenopathy and could not detect any cause for his symptoms, he was referred to our hospital for further investigation. On admission, he was febrile (37.4 °C). Physical examination showed epigastric tenderness without signs of peritoneal irritation, and pitting edema on the lower extremities. His laboratory test results on admission are shown in Table 1. Contrast-enhanced CT scan revealed cervical, supraclavicular, axillary, paraaortic and inguinal lymphadenopathies, bilateral pleural effusion, ascites and hepatosplenomegaly. Soon after his admission, hemodialysis and mechanical ventilation were initiated due to the development of anuria and dyspnea, and methylprednisolone pulse therapy (1 g/day) was administered for three days after ruling out bacterial infections on hospital day 9, followed by intravenous methylprednisolone (50 mg/day) as maintenance therapy. Laboratory data on hospital day 11 are shown in Table 2. In spite of hemodialysis and ventilatory support, his vital signs were unstable, necessitating temporary use of catecholamines to maintain his blood pressure. Additionally, his plasma calcium level decreased (ionized calcium: 0.78 mmol/L) with a high level of phosphorus (9.6 mg/dL) on hospital day 17. Subsequently, we intravenously administered calcium gluconate hydrate for a total of eight days because the hypocalcemia was refractory to therapy. Laboratory data indicated low vitamin D and high intact parathyroid hormone levels, as seen in patients with chronic kidney disease. Finally, his plasma calcium levels were maintained within the normal range (Fig. 1). Bone marrow biopsy revealed hypercellular marrow with an increased number

| Table 1 Laboratory data on admission |
|--------------------------------------|
| **Complete blood cell count**         | **Blood chemistry**                   |
| WBC 14,100 /μL                       | Total protein 5.1 g/dL                |
| Seg 143 /μL                          | Albumin 1.8 g/dL                      |
| Eosino 83 /μL                         | TBil 1.0 mg/dL                        |
| Lympho 7 %                           | AST 29 IU/L                           |
| Mono 9 %                             | ALT 14 IU/L                           |
| RBC 413 /μL                          | LDH 370 IU/L                          |
| Hgb 13.5 g/dL                        | ALP 265 IU/L                          |
| MCV 86.2 fl                          | γ-GTP 105 IU/L                        |
| Platelet 46.8 /μL                    | BUN 43.1 mg/dL                        |
| Coagulation system                   | Cr 1.62 mg/dL                         |
| PT 18.2 sec                          | eGFR 46 mL/min/1.73m²                |
| PT-INR 1.5                           | CRP 25.37 mg/dL                       |
| APTT (standard: 26-36) 47.9 sec      | Glu 78 mg/dL                         |
| Fibrinogen >600 mg/dL                | AMY 39 IU/L                          |
| D-dimer 26.9 μg/mL                   |                                           |

WBC: White blood cell, RBC Red blood cell, Hgb Hemoglobin, MCV Mean corpuscular volume, PT Prothrombin time, PT-INR Prothrombin time-international normalized ratio, APTT Activated partial thromboplastin time, TBil Total Bilirubin, AST Aspartate aminotransferase, ALP Alanine aminotransferase, LDH Lactate dehydrogenase, ALP Alkaline phosphatase, BUN Blood urea nitrogen, Cr Creatinine, CRP C-reactive protein, AMY Amylase
of megakaryocytes (Fig. 2). Based on these findings and exclusion criteria, we diagnosed his condition as TAFRO syndrome according to the diagnostic criteria proposed in 2015 [3].

We initiated weekly treatment with the biologic tocilizumab (8 mg/kg), which is a recombinant, humanized, anti-human interleukin-6 (IL-6) receptor monoclonal antibody, along with tapering glucocorticoids on hospital day 32. However, on hospital day 76, he presented with syncope due to sick sinus syndrome. We first recognized myocardial and skeletal muscle calcification by CT scans on hospital day 47 (Fig. 3). Subsequent CTs showed progressive worsening of the degree of calcification in the first few months (Fig. 4). At this time, we could not perform temporary pacing because of the risk of hemorrhage due to persistently low platelet levels and coagulopathy.

Although he repeatedly suffered from various infections (such as catheter related blood stream infection, pyothorax, intraabdominal abscess and infectious endocarditis), we basically continued use of tocilizumab, except when the infection was very severe. We initiated romiplostim, an analog of thrombopoietin, on day 173 because his platelet count remained persistently low, which soon resulted in recovery of platelet count to within the normal range. In addition, urine volume began to gradually increase five months after the onset of anuria. Thereafter, calcification of the rectus abdominis muscle also began to gradually diminish, as observed by CT scans, although there were no remarkable changes in that of the myocardium (Fig. 4).

Although there were many life-threatening events throughout his prolonged hospitalization, he was finally discharged from the hospital in an ambulatory condition on hospital day 410 (his complete clinical course is shown in Fig. 5). Sick sinus syndrome resolved together with improvement in his general condition, so permanent pacemaker implantation was deemed unnecessary. Currently, he receives regular hemodialysis and

### Table 2 Laboratory data at the time of diagnosis of TAFRO syndrome

| Complete blood cell count | Blood chemistry | Immunologic test |
|---------------------------|----------------|-----------------|
| WBC 23,600 /μL | Albumin 1.5 g/dL | IgG 1385 mg/dL |
| Band 6 % | T.Bil 0.4 mg/dL | IgG4 66 mg/dL |
| Seg 88 % | AST 33 IU/L | IgA 187 mg/dL |
| Lympho 3 % | ALT 12 IU/L | IgM 62 mg/dL |
| Mono 3 % | LDH 471 IU/L | ANA <40 times |
| RBC 348 10^6/μL | γ-GTP 266 IU/L | anti-RNP Ab – |
| Hgb 9.9 g/dL | ALP 400 IU/L | anti-ds-DNA IgG – |
| MCV 86.8 fl | Ferritin 1873 ng/mL | anti-SS-A Ab – |
| Platelet 7.5 10^9/μL | Cr 7.77 mg/dL | RF <3 IU/mL |
| ESR 87 mm/hr | LDH 471 IU/L | PLT-INR 1.59 |
| IgG 1385 mg/dL | ANA <40 times | IL-6 65.1 pg/mL |
| IgA 187 mg/dL | anti-RNP Ab – | VEGF 1030 pg/mL |
| IgM 62 mg/dL | anti-ds-DNA IgG – | |
| IgG4 66 mg/dL | anti-SS-A Ab – | |
| Band 6 % | anti-RNP Ab – | |
| Seg 88 % | anti-ds-DNA IgG – | |
| Lympho 3 % | anti-SS-A Ab – | |
| Mono 3 % | PLT-INR 1.59 | |
| RBC 348 10^6/μL | VEGF 1030 pg/mL | |
| Hgb 9.9 g/dL | anti-SS-A Ab – | |
| MCV 86.8 fl | anti-ds-DNA IgG – | |
| Platelet 7.5 10^9/μL | anti-SS-A Ab – | |
| ESR 87 mm/hr | anti-ds-DNA IgG – | |
| IgG 1385 mg/dL | anti-SS-A Ab – | |
| IgA 187 mg/dL | anti-ds-DNA IgG – | |
| IgM 62 mg/dL | anti-ds-DNA IgG – | |
| IgG4 66 mg/dL | anti-ds-DNA IgG – | |
| Band 6 % | anti-ds-DNA IgG – | |
| Seg 88 % | anti-ds-DNA IgG – | |
| Lympho 3 % | anti-ds-DNA IgG – | |
| Mono 3 % | anti-ds-DNA IgG – | |
| RBC 348 10^6/μL | anti-ds-DNA IgG – | |
| Hgb 9.9 g/dL | anti-ds-DNA IgG – | |
| MCV 86.8 fl | anti-ds-DNA IgG – | |
| Platelet 7.5 10^9/μL | anti-ds-DNA IgG – | |
| ESR 87 mm/hr | anti-ds-DNA IgG – | |
| IgG 1385 mg/dL | anti-ds-DNA IgG – | |
| IgA 187 mg/dL | anti-ds-DNA IgG – | |
| IgM 62 mg/dL | anti-ds-DNA IgG – | |
| IgG4 66 mg/dL | anti-ds-DNA IgG – | |
| Band 6 % | anti-ds-DNA IgG – | |
| Seg 88 % | anti-ds-DNA IgG – | |
| Lympho 3 % | anti-ds-DNA IgG – | |
| Mono 3 % | anti-ds-DNA IgG – | |
| RBC 348 10^6/μL | anti-ds-DNA IgG – | |
| Hgb 9.9 g/dL | anti-ds-DNA IgG – | |
| MCV 86.8 fl | anti-ds-DNA IgG – | |
| Platelet 7.5 10^9/μL | anti-ds-DNA IgG – | |
| ESR 87 mm/hr | anti-ds-DNA IgG – | |
| IgG 1385 mg/dL | anti-ds-DNA IgG – | |
| IgA 187 mg/dL | anti-ds-DNA IgG – | |
| IgM 62 mg/dL | anti-ds-DNA IgG – | |
| IgG4 66 mg/dL | anti-ds-DNA IgG – | |
| Band 6 % | anti-ds-DNA IgG – | |
| Seg 88 % | anti-ds-DNA IgG – | |
| Lympho 3 % | anti-ds-DNA IgG – | |
| Mono 3 % | anti-ds-DNA IgG – | |
| RBC 348 10^6/μL | anti-ds-DNA IgG – | |
| Hgb 9.9 g/dL | anti-ds-DNA IgG – | |
| MCV 86.8 fl | anti-ds-DNA IgG – | |
| Platelet 7.5 10^9/μL | anti-ds-DNA IgG – | |
| ESR 87 mm/hr | anti-ds-DNA IgG – | |
| IgG 1385 mg/dL | anti-ds-DNA IgG – | |
| IgA 187 mg/dL | anti-ds-DNA IgG – | |
| IgM 62 mg/dL | anti-ds-DNA IgG – | |
| IgG4 66 mg/dL | anti-ds-DNA IgG – | |
| Band 6 % | anti-ds-DNA IgG – | |
| Seg 88 % | anti-ds-DNA IgG – | |
| Lympho 3 % | anti-ds-DNA IgG – | |
| Mono 3 % | anti-ds-DNA IgG – | |
| RBC 348 10^6/μL | anti-ds-DNA IgG – | |
| Hgb 9.9 g/dL | anti-ds-DNA IgG – | |
| MCV 86.8 fl | anti-ds-DNA IgG – | |
| Platelet 7.5 10^9/μL | anti-ds-DNA IgG – | |
| ESR 87 mm/hr | anti-ds-DNA IgG – | |
| IgG 1385 mg/dL | anti-ds-DNA IgG – | |
| IgA 187 mg/dL | anti-ds-DNA IgG – | |
| IgM 62 mg/dL | anti-ds-DNA IgG – | |
| IgG4 66 mg/dL | anti-ds-DNA IgG – | |

WBC White blood cell, RBC Red blood cell, Hgb Hemoglobin, MCV Mean corpuscular volume, ESR Erythrocyte sedimentation rate, EBV Epstein–Barr virus, VCA Virus capsid antigen, EBNA Epstein–Barr virus nuclear antigen, CMV Cytomegalovirus, HIV Human immunodeficiency virus, Ab Antibody, HHV-8 Human herpesvirus-8, IGRA Interferon-gamma releasing assay, T.Bil Total Bilirubin, AST Aspartate aminotransferase, ALTAlanine aminotransferase, LDH Lactate dehydrogenase, γ-GTP Gamma-glutamyl transpeptidase, ALP Alkaline phosphatase, BUN Blood urea nitrogen, Cr Creatinine, CRP C-reactive protein, ACE Angiotensin-converting enzyme, PT Prothrombin time, PT-INR Prothrombin time-international normalized ratio, APTT Activated partial thromboplastin time, AT-III Antithrombin III, FDP Fibrin/fibrinogen degradation products, ANA Antinuclear antibody, anti-RNP-antibody Anti-Ribonucleoprotein antibody, anti-ds-DNA IgG Anti-double-stranded deoxyribonucleic acid immunoglobulin G, anti-SS-A antibody Anti-Sjögren's syndrome A antibody, RF Rheumatoid factor, PR3-ANCA Proteinase 3-anti-neutrophil cytoplasmic antibody, MPO-ANCA Myeloperoxidase-anti-neutrophil cytoplasmic antibody, PA-IgG Platelet-associated immunoglobulin G, anti-GBM antibody Anti-glomerular basement membrane antibody, sIL-2R Soluble interleukin-2 receptor, IL-6 Interleukin-6, VEGF Vascular endothelial growth factor
in intravenous tocilizumab every three weeks without evidence of recurrence for one year after discharge.

**Discussion**

**TAFRO syndrome and cardiac events**

TAFRO syndrome is defined as a subtype of idiopathic multicentric Castleman’s disease (iMCD) that has been recognized as having a severe clinical course. Masaki et al. proposed the diagnostic criteria and severity classification in 2015, and there have been several recently reported clinicopathological analyses and consensus guidelines for the treatment of iMCD based on the accumulated data [2–5]. Our case fulfilled the diagnostic criteria of TAFRO syndrome according to the guideline, and

---

**Fig. 1** Transition of ionized calcium. Hypocalcemia appeared after the initiation of dialysis, and myocardial/skeletal muscle calcification was revealed on CT scans after the recovery from hypocalcemia with administration of calcium gluconate hydrate.

**Fig. 2** Histological findings on bone marrow biopsy: a, b Hypercellular marrow with increased megakaryocytes are seen. (Hematoxylin and eosin staining). (Scale bar, 100 μm)
was classified as grade 4 (severe) severity. Our case is rare not only because of many life-threatening events such as repetitive severe infections, sick sinus syndrome and cardiac arrest, but also because of the myocardial and skeletal muscle calcification that occurred two months after his disease onset. Other cases have also survived despite a very severe clinical course [9–11], although none of them experienced systemic calcification.

Many TAFRO syndrome cases have recovered with the use of biological products (such as tocilizumab or rituximab), glucocorticoids, immunosuppressants (such as cyclosporine A or sirolimus), and occasionally, with chemotherapy. In terms of cardiac dysfunction, Yasuda et al. reported two cases of TAFRO syndrome with cardiomyopathy and lowered ejection fraction (EF) [6]. They performed CHOP (cyclophosphamide, adriamycin, vincristine and prednisolone) therapy as treatment, and assumed that the cardiomyopathy was an adverse effect of adriamycin. Hiramatsu et al. showed a case of TAFRO syndrome with reversible cardiomyopathy, in which they opined that the high concentration of plasma IL-6 was the cause of cardiomyopathy [7]. However, these cases did not have any associated calcification.

**The etiology of myocardial/systemic calcification**

Myocardial calcification itself only occurs very rarely. There are traditionally two pathways causing myocardial calcification: metastatic and dystrophic. Metastatic calcification occurs with hypercalcemia and/or abnormality of calcium/phosphate metabolism [12]. This form of calcification can occur anywhere in the body, but is more likely in areas of high alkalinity, such as the gastric mucosa or systemic arteries; therefore, calcification due to this etiology can exist systemically. On the other hand, dystrophic calcification occurs secondary to cellular damage and necrosis, with calcium deposits replacing necrotizing cells. Other etiologies of dystrophic calcification include trauma, infections, inflammation, neoplasms and drugs [12]. Myocardial infarction is a common cause of myocardial calcification. Septic shock is also a cause of this form of calcification; hypotension during shock and catecholamine use can cause myocardial damage, which eventually results in calcium deposits even if plasma calcium concentration is normal [12, 13]. In our case, the etiology of myocardial and skeletal muscle calcification was considered more likely to be metastatic than dystrophic due to the following reasons. First, there was a failure of calcium/phosphate metabolism due to the presence of progressive renal dysfunction with hemodialysis and low vitamin D levels. There was also excessive replenishment of calcium, with an amount of 7.8 mmol of calcium gluconate hydrate per day on average, which could have accelerated calcium deposition in systemic tissues. We did not administer intravenous vitamin D agents, except for the minimal amount of vitamins administered through total parenteral nutrition, which might have been a possible cause for prolonged low calcium levels. Second, both myocardial and skeletal muscle calcification were detected on CT scans at the same time, which was within a month after the initial identification of hypocalcemia and subsequent overloading of calcium (Fig. 3). Third, although we temporarily used catecholamines, there were no other conditions explaining the dystrophic calcification, such as septic shock or myocardial infarction. Fourth, hypercytokinemia, including elevated IL-6 caused by TAFRO syndrome, could also have contributed to this unusual situation. Plasma calcium levels remained low and were almost unchanged when calcium gluconate hydrate was administered, which suggested that the administered calcium probably leaked out of the vessels and was absorbed by peripheral tissues. Increase of vasopermeability is another possible etiology for the
Fig. 4  Chronological changes in myocardial and skeletal muscle (rectus abdominis) calcification on computed tomography images. Computed tomography was performed on (a, e) day 47, (b, f) day 123, (c, g) day 177 and (d, h) day 345. The degree of calcification showed progressive worsening during the first few months; subsequently, myocardial calcification remained unchanged, while that in the skeletal muscle gradually diminished.

Fig. 5  Clinical course from admission until discharge. PLT platelets, CRP C-reactive protein, mPSL methylprednisolone, TCZ tocilizumab, HD hemodialysis, CRBSI catheter-related blood stream infection, IE infectious endocarditis, SSS sick sinus syndrome.
calcified deposits, which could explain its occurrence in the absence of hypercalcemia.

In conclusion, this case of TAFRO syndrome achieved a successful recovery with tocilizumab therapy along with prolonged hospitalization, although he experienced the unexpected complication of myocardial and skeletal muscle calcification probably via a metastatic pathway triggered by drug administration. In acute clinical settings, the tendency is to urgently correct abnormal laboratory data, especially electrolyte abnormalities. However, TAFRO syndrome is known to be associated with hypercytokinemia and organ dysfunction with an unknown pathophysiology; hence, the general management of such cases should be carefully handled, anticipating unexpected complications.

Abbreviations
TAFRO: Thrombocytopenia, anasarca, fever, renal insufficiency or reticulin fibrosis, and organomegaly; iMCD: Idiopathic multicentric Castleman’s disease; CT: Computed tomography; IL-6: Interleukin-6; CHOP: Cyclophosphamide, adriamycin, vincristine and prednisolone.

Acknowledgements
The authors thank Forte Science Communications (www.forte-science.co.jp) for their assistance in proofreading this article.

Authors’ contributions
SM treated this patient, reviewed literature, interpreted the patient data about the etiology in this patient, and contributed to writing the manuscript. YF reviewed literature, wrote the manuscript, and managed this research. KS treated this patient and wrote the manuscript. AT provided professional opinions regarding patient care and treatment, and revised the manuscript. KN revised the manuscript and currently cares for this patient at the outpatient clinic. All authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Ethics approval and consent for submitting case reports is usually waived by the ethics review committee of Musashino Red Cross Hospital. We followed the principles of the Declaration of Helsinki and paid cautious attention to protecting the patient’s identity.

Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of General Internal Medicine, Musashino Red Cross Hospital, 1-26-1, Kyonancho, Musashino-shi, Tokyo 1808610, Japan. 2 Department of Medical Oncology, Musashino Red Cross Hospital, 1-26-1, Kyonancho, Musashino-shi, Tokyo 1808610, Japan. 3 Department of Nephrology, Musashino Red Cross Hospital, 1-26-1, Kyonancho, Musashino-shi, Tokyo 1808610, Japan. 4 Department of Rheumatology and Collagen Disease, Musashino Red Cross Hospital, 1-26-1, Kyonancho, Musashino-shi, Tokyo 1808610, Japan. 5 Department of Medical Oncology, Musashino Red Cross Hospital, 1-26-1, Kyonancho, Musashino-shi, Tokyo 1808610, Japan.

Received: 19 August 2020 Accepted: 17 November 2020
Published online: 06 January 2021

References
1. Takai K, Nikkuni K, Shibuya H, Hashidate H. Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly. Rinsho Ketsueki (The Japanese Journal of Clinical Hematology). 2010;51(5):320–5 (Abstract in English).
2. Iwaki N, Fajgenbaum DC, Nabel CS, Gion Y, Kondo E, Kawano M, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol. 2016;91(2):220–6.
3. Masaki Y, Kawabata H, Takai K, et al. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol. 2016;103:686–92.
4. van Rheez F, Voorhees P, Dinkenberger A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132(20):2115–24.
5. Fajgenbaum DC. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. Blood. 2018;132(22):2332–30.
6. Yasuda S, Tanaka K, Ichikawa A, et al. Aggressive TAFRO syndrome with reversible cardiomyopathy successfully treated with combination therapy. Int J Hematol. 2016;104:512–8.
7. Hiramatsu S, Ohmura K, Tsuji H, et al. Successful treatment by rituximab in a patient with TAFRO syndrome and cardiomyopathy. Jpn J Clin Immunol. 2016;39(1):64–71.
8. Okumura M, Ujiro A, Otsuka Y, et al. Cardiac arrest caused by rapidly increasing ascites in a patient with TAFRO syndrome: a case report. Acute Med Surg. 2017;4(3):344–8.
9. Suzuki K, Matsumoto T, Iwashita Y, et al. Clinicopathological features of TAFRO syndrome complicated by acquired hemophilia A and development of cardiopulmonary arrest that were successfully treated with VA-ECMO and tocilizumab. Int J Hematol. 2019;109(6):737–43.
10. Takayama Y, Kubota T, Ogo Y, Ohnishi H, Togitani K, Yokoyama A. TAFRO syndrome with disseminated intravascular coagulation successfully treated with tocilizumab and recombinant thrombomodulin. Intern Med. 2018;57(9):1291–6.
11. Fujiki T, Hirasawa S, Watanabe S, Iwamoto S, Ando R. Successful treatment by tocilizumab without steroid in a very severe case of TAFRO syndrome. Intern Med. 2017;56(1):102–9.
12. Nance JW Jr, Crane GM, Halushka MK, Fishman EK, Zimmerman SL. Myocardial calcification: pathophysiology, etiologies, differential diagnoses, and imaging findings. J Cardiovasc Comput Tomogr. 2015;9(1):58–67.
13. Tominaga N, Oishi D, Kida K, Kimura K, Shiibagaki Y. Rapidly developed diffuse myocardial calcification 13 days after septic shock in a hemodialysis patient. CEN Case Rep. 2014;3(2):244–5.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.